Medicine and Dentistry
Circulating Tumor Cell
100%
Biological Marker
87%
Neoplasm
68%
Malignant Neoplasm
46%
Diseases
45%
Bevacizumab
38%
Vasculotropin Inhibitor
34%
Small Cell Lung Cancer
32%
Cancer Cell
32%
Cancer Surgery
32%
COVID-19
32%
Blood Vessel Reactivity
32%
Overall Survival
27%
Progression Free Survival
27%
Cediranib
24%
Advanced Cancer
24%
Nodular Melanoma
23%
Immunohistochemistry
23%
Programmed Cell Death
21%
Colorectal Cancer
21%
Krukenberg Tumor
21%
Ovarian Cancer
21%
Vasculotropin Receptor 2
20%
Surgery
20%
Recurrent Disease
20%
Metastatic Carcinoma
19%
Antiangiogenic
19%
Biomarker Study
19%
Non Small Cell Lung Cancer
17%
Lung Cancer
17%
Hazard Ratio
16%
Anti-biotics
16%
Vasculotropin A
16%
Androgen Receptor
16%
Nivolumab
16%
Ipilimumab
16%
Biliary Tract Cancer
16%
Lung Adenocarcinoma
16%
Recurrent Ovarian Cancer
16%
In Vitro
16%
Cutaneous Melanoma
16%
Pazopanib
16%
Combretastatin A4 Phosphate
16%
Infection
16%
Retrospective Study
16%
Non-Small Cell Lung Cancer
16%
Cell Survival
16%
Hepatocellular Carcinoma
16%
Cervical Cancer
16%
Pulmonary Vein
16%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
99%
Vasculotropin Inhibitor
54%
Ovary Cancer
50%
Bevacizumab
47%
Malignant Neoplasm
41%
Progression Free Survival
40%
Melanoma
38%
Overall Survival
32%
Non Small Cell Lung Cancer
32%
Vascular Tumor
32%
Neoplasm
31%
Disease
30%
Cediranib
24%
Antiangiogenic
21%
Brain Metastasis
18%
Antibiotics
16%
Retrospective Study
16%
Uterine Cervix Cancer
16%
Metastatic Colorectal Cancer
16%
Ipilimumab
16%
Pancreas Cancer
16%
Protein Tyrosine Kinase Inhibitor
16%
Biliary Tract Cancer
16%
Cutaneous Melanoma
16%
Colorectal Cancer
16%
Combretastatin A4 Phosphate
16%
Pazopanib
16%
Vasculotropin A
16%
Pancreas Adenocarcinoma
16%
Nivolumab
16%
Disease Exacerbation
10%
Metastasis
8%
Adverse Event
8%
Immunotherapy
8%
Placebo
7%
Lactate Dehydrogenase
7%
Glypican 3
5%
Paclitaxel
5%
Carboplatin
5%
Enzyme-Linked Immunosorbent Assay
5%
Advanced Cancer
5%
Observational Study
5%
Ovary Carcinoma
5%
Vaccination Policy
5%
Distress Syndrome
5%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
68%
Vascular Endothelial Growth Factor
58%
Progression Free Survival
49%
Proteomics
48%
Blood Vessel Reactivity
48%
Overall Survival
33%
Cediranib
24%
Cell Count
24%
Dynamics
22%
Kinase Insert Domain Receptor
20%
Angiogenesis
19%
Biomarker Study
19%
Isobaric Tag for Relative and Absolute Quantitation
16%
Angiopoietin 1
16%
DNA Sequence
16%
Observational Study
16%
Somatic Mutation
16%
Decision Support System
16%
SARS Coronavirus
16%
Carcinogenesis
16%
Gene Network
16%
Vascular Endothelial Growth Factor A
16%
Cell Function
16%
Glypican 3
16%
Mortality Rate
16%
T Cell
16%
Tyrosine Kinase Inhibitor
16%
Neuroendocrine Cell
16%
Normal Human
16%
T Cell Receptor
16%
Immune Checkpoints
15%
Pharmacodynamics
13%
Blood Plasma
13%
Mouse Model
13%
Genetically Engineered Mouse Strain
13%
Blood Level
11%
Mass Spectrometry
10%
Explant
9%
CA-125
9%
Next Generation Sequencing
8%
Escherichia coli
8%
Random Forest
8%
Tandem Mass Spectrometry
8%
Sample Size
8%
Clonality
6%
Tumor Progression
6%
Clonal Variation
6%
Integrin
6%
Mouse
5%
Cell Lysate
5%